Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLF10 | Q13118 | 1/20 | 0.43 |
| ▸ | POLQ | O75417 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993639 | 0.86 | CES2 (0.52) | POLQCYP2D6CES2DAOAR | |
| SCHEMBL1447610 | 0.86 | KLF10 (0.47) | KLF10CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL102128 | 0.85 | CES2 (0.43) | KLF10POLQKIF11CYP2D6CES2 | |
| SCHEMBL25530518 | 0.83 | CYP1A2 (0.41) | POLQCYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL25562870 | 0.81 | DAO (0.42) | POLQCYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL25530531 | 0.80 | PDE3B (0.45) | POLQCYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL25594632 | 0.80 | CYP2C19 (0.64) | POLQCYP1A2CYP2C19ALOX15KIF11 | |
| SCHEMBL22275799 | 0.79 | KLF10 (0.53) | KLF10CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL14297625 | 0.78 | EPHX2 (0.44) | KLF10CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL7979494 | 0.78 | KLF10 (0.47) | KLF10CYP1A2CYP2C19ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642576-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KLF10 3933/4885POLQ 891/4885CYP1A2 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.